805 related articles for article (PubMed ID: 27955647)
1. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
[TBL] [Abstract][Full Text] [Related]
2. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
4. Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Uutela T; Kautiainen H; Järvenpää S; Salomaa S; Hakala M; Häkkinen A
Scand J Rheumatol; 2015 May; 44(3):173-81. PubMed ID: 25438985
[TBL] [Abstract][Full Text] [Related]
5. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
[TBL] [Abstract][Full Text] [Related]
6. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
8. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.
Lampropoulos CE; Orfanos P; Bournia VK; Karatsourakis T; Mavragani C; Pikazis D; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2015; 33(2):216-24. PubMed ID: 25664400
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
[TBL] [Abstract][Full Text] [Related]
10. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
[TBL] [Abstract][Full Text] [Related]
11. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
[TBL] [Abstract][Full Text] [Related]
12. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
[TBL] [Abstract][Full Text] [Related]
13. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
14. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
15. Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage On Rheumatic Disease study on administrative healthcare databases.
D'Amico ME; Silvagni E; Carrara G; Zanetti A; Govoni M; Scirè CA; Bortoluzzi A
Scand J Rheumatol; 2021 Sep; 50(5):333-342. PubMed ID: 33660559
[No Abstract] [Full Text] [Related]
16. Ten-year retrospective review of the incidence of serious infections in patients on biologic disease modifying agents for rheumatoid arthritis in three tertiary hospitals in Western Australia.
Sharma C; Keen H
Intern Med J; 2019 Apr; 49(4):519-525. PubMed ID: 30230146
[TBL] [Abstract][Full Text] [Related]
17. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology.
Carrara G; Bortoluzzi A; Sakellariou G; Silvagni E; Zanetti A; Govoni M; Scirè CA
Clin Exp Rheumatol; 2019; 37(1):60-66. PubMed ID: 30148440
[TBL] [Abstract][Full Text] [Related]
18. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
19. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease.
Richards JS; Dowell SM; Quinones ME; Kerr GS
BMJ; 2015 Aug; 351():h3658. PubMed ID: 26282936
[TBL] [Abstract][Full Text] [Related]
20. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis.
Batko B; Urbański K; Świerkot J; Wiland P; Raciborski F; Jędrzejewski M; Koziej M; Cześnikiewicz-Guzik M; Guzik TJ; Stajszczyk M
Clin Rheumatol; 2019 Sep; 38(9):2473-2481. PubMed ID: 31076943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
